Status: Not yet recruiting
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang UniversityUpdated: Jul 30, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years. [+10]
Prior treatment with drugs similar to the investigational product. [+17]